Skip to main content
. 2022 Jun 20;2022:3191569. doi: 10.1155/2022/3191569

Table 1.

Prognostic difference between HPV(+) and HPV(−) HNSCC.

HPV(+) HPV(−)
Mutational load Lower Higher
Cell differentiation Low Marked
5-year survival rate 75–80% <50%
Biomarkers Overexpression of P16, inactivation of p53 Loss of P16, p53 mutation
Metastasis Infrequent Frequent
Radiosensitive/chemosensitive +++ +